Kangchen Pharmaceutical co-organized the 2021 "Expert Consensus on the Prevention and Treatment of Acute Bone Loss in Orthopedics" city lecture tour project was officially launched

In order to care for bone health and help healthy China 2030 strategy, the city tour of "Expert Consensus on The Prevention and Control of Acute Bone Loss in Orthopedics" was successfully held in Zhengzhou with the strong cooperation of Kangchen Pharmaceutical (603590) and harvested. More than 80 clinicians attended the meeting were from orthopedics, spine surgery, rehabilitation, geriatrics, internal medicine, pain and other departments, of which more than 80% of the experts attending the meeting were from orthopedics.

At present, China has entered an aging society, and osteoporosis has become an important public health problem facing us. Bone loss is widespread in orthopedic clinics, and if the harm is not stopped in time, it will lead to the failure of orthopedic surgery in the short term, and the long-term osteoporosis of patients will come early and the risk of fracture will increase. In July 2021, the Osteoporosis Prevention and Rehabilitation Professional Committee of the Chinese Rehabilitation Medicine Association joined hands with national orthopedic experts to jointly discuss and summarize the history, status, etiology, assessment and prevention of acute bone loss research, and completed and released the first edition of the world's "Expert Consensus on the Prevention and Treatment of Orthopedic Acute Bone Loss". The consensus points out that drug intervention is the focus of treatment to prevent acute bone loss, and Migai is the only anti-osteosone drug with indications to prevent bone loss, and has a unique dual analgesic mechanism in analgesia, which meets the characteristics of the ideal prevention and treatment of bone loss drugs, and is an ideal choice for bone loss and bone loose patients.

In order to benefit more doctors and patients with consensus results, the Chinese Journal of Bone and Joint Surgery and the "Professional Committee of Osteoporosis Prevention and Rehabilitation of the Chinese Rehabilitation Medicine Association" will work together to carry out a series of online and offline consensus interpretation national tour starting in October 2021. Kangchen Pharmaceutical actively participates in the implementation of this project throughout the process, practices corporate responsibility with practical actions, adheres to the core mission of "caring for human health with life sciences", focuses on the field of bone disease health, and is committed to providing the best quality services for orthopedic doctors and patients.

In the next step, the "Orthopedic Acute Bone Loss Prevention and Control Expert Consensus" city tour will be held in Nanchang, Xi'an, Jinan, Wuhan, Kunming and other parts of the country, Kangchen Pharmaceutical will continue to fully support the implementation of this project, for the standardized prevention and treatment of bone loss patients to add help, in order to better benefit the majority of bone loss and osteoporosis patients in China! (Yanyun)

【Source: Securities Times Network】

Disclaimer: The copyright of this article belongs to the original author, if there is an error in the source or infringement of your legitimate rights and interests, you can contact us through the mailbox, we will deal with it in a timely manner. Email address: [email protected]